Biotech Startups

2 investors

Ephemeral develops biodegradable tattoo ink designed to fade over time, offering a non-permanent alternative to traditional tattoos without laser removal. Founded by NYU PhD researchers, the company sells its black fade-away ink through partner tattoo artists and operates a studio in Brooklyn, New York.

2 investors

2 investors

EPICS Therapeutics develops RNA epigenetics-based cancer treatments, focusing on METTL3 inhibitors for cancers including non-small cell lung cancer, pancreatic cancer, ovarian cancer, and colorectal cancer where existing therapies are insufficient.

2 investors

EPICS is a biotech company developing plant biology and protein engineering technology to produce agricultural inputs such as crop protection products and biostimulants. It applies plant molecular farming and epigenetics research to create scalable expression systems for high-value protein production in agriculture.

2 investors

Epidarex is a venture capital firm that invests equity in early-stage life science and health technology companies, particularly university spin-outs and startups in under-ventured research hubs across the UK and US. The firm leverages its network of scientists, industry executives, and regulatory experts to support portfolio companies in translating research into commercial healthcare businesses.

2 investors

Epigene Labs develops AI-powered tools for analyzing genomic data and precision oncology research, serving biopharmaceutical companies and cancer researchers. The company builds software platforms and conducts translational research to support the development of personalized cancer therapies.

2 investors

Epigenica is a life sciences company working in multi-omics, biomarker discovery, and diagnostics. It develops advanced technologies for the life science and healthcare sectors.

2 investors

Epigenic Therapeutics develops gene regulation-based biotherapeutics using its EPIREG platform, which applies AI algorithms to design CRISPR-Cas components that regulate target gene expression without altering the DNA sequence. Combined with a lipid nanoparticle delivery system, the technology targets metabolic, cardiovascular, viral hepatitis, ocular, oncology and rare diseases.

2 investors

Epiliquid develops blood-based molecular tests for cancer detection and differential diagnosis using a platform that combines AI-driven methylation biomarker discovery, patented native-DNA assay chemistry, and PCR-based readout. Its technology measures multiple methylation biomarkers in a single PCR reaction and runs on the qPCR and digital PCR instruments clinical laboratories already use, serving precision oncology.

2 investors

Epion Therapeutics develops a minimally-invasive cross-linking treatment system called EpiSmart for keratoconus, a corneal disease, designed to preserve vision without disrupting the corneal epithelium. The company aims to bring early intervention treatment to patients globally.

2 investors

Epistemic AI automates strategic intelligence deliverables for life sciences companies, including competitive landscapes, target product profiles, and conference analysis. The platform uses AI-powered automation validated by life science experts to deliver structured, evidence-backed strategic documents traditionally requiring months of consulting work.

2 investors

Epitomee develops ingestible therapeutic devices and platforms that deliver targeted therapies along the gastrointestinal tract to manage metabolic diseases, obesity, and deliver biologics. The company combines mechanical and ingestible morphology platforms with therapeutic agents to achieve specific localization with limited side effects.

2 investors

Erisyon is a biotechnology company that develops technology to advance scientific and health discoveries, building on research from the University of Texas at Austin's Center for Systems and Synthetic Biology. It was founded in 2018 by a group of technologists and entrepreneurs.

2 investors

EsoCap AG is a clinical-stage Swiss biotech company developing treatments for esophageal diseases. The company is led by an experienced industry team with clinical development expertise.

2 investors

Esperovax develops oral mRNA vaccines delivered as pills or gummies that synthesize the mRNA in the intestines, where 70% of the immune system resides. The company aims to address production and logistical challenges of traditional mRNA vaccines while improving patient acceptance.

2 investors

Esphera designs transgenes that enable budding exosomes to carry multimeric proteins for therapeutic applications, with initial focus on modifying tumor-derived exosomes to create immunostimulatory cancer vaccines.

2 investors

Ethyreal Bio is a biopharmaceutical company developing medicines for people with Thyroid Eye Disease and Graves' Disease. It focuses on antibody and other therapeutic programs in the endocrine/immunology space.

2 investors

EuMentis Therapeutics develops therapies for neuropsychiatric disorders, targeting selective CNS circuits in the brain. Its lead product, EM-221, is a PDE10A inhibitor in development for schizophrenia and Parkinson's levodopa-induced dyskinesia, with a pipeline addressing conditions such as Alzheimer's-related agitation, treatment-resistant depression, bipolar disorder, and Tourette's.

2 investors

EurekaBio develops technologies and solutions for the cell and gene therapy (CGT) industry, focused on treatments for diseases such as cancer, rare diseases, genetic disorders, and auto-immune conditions. The company positions itself as a provider of comprehensive, research-driven solutions to CGT challenges.

2 investors

EV Biotech designs and optimizes precision fermentation strains and processes for clients seeking sustainable production methods. The company reprograms microorganisms to enable industrial-scale fermentation as an alternative to resource-intensive manufacturing.

2 investors

EVL Bio is developing a selective anti-FGFR4 monoclonal antibody therapy to treat left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD). The therapy blocks pathological FGF23–FGFR4 signaling in cardiomyocytes to prevent maladaptive cardiac hypertrophy and fibrosis.

2 investors

Evodia is a Danish aroma company that uses precision fermentation with proprietary yeast strains to produce monoterpenes, the natural molecules behind flavor and aroma, as a sustainable alternative to plant-derived ingredients. Its Yops product provides customizable aroma blends for brewers, positioned as an alternative to hops in non-alcoholic and alcohol-free beer.

2 investors

Evolva (EvoNext Holdings SA / Evolva Holding AG) develops and markets flavour and fragrance products. The page is an investor relations section providing financial information and shareholder resources for the publicly listed company.

2 investors